Acronym: MAGIC, MAnufacturing of Gene delivery tools for Industrial and Clinical applications.
The goal is to up-grade its scalable lentiviral bioproduction platform into GMP to provide both integrative lentiviral vectors for T-cell immunotherapies and LentiFlashTM particles for gene-editing and vaccine based therapies.
Lentifactory, a project funded from the Horizon 2020 programme, will focus on:
- A GMP scalable manufacturing platform as a response to the lack of expert clinical manufacturing infrastructure in Europe
- An innovative and non-integrative lentiviral particle, LentiFlash, as a response to the needs of the vaccine and gene-editing market
Fully in line with the work programme’s objectives, this project will provide a revolutionise way to the transfection market, especially throughout Europe.